Upon completion of the acquisition, which is subject to definitive agreements, Enzo will have local, directly owned presence from which to market its growing line of life sciences reagents and systems. The acquisition is expected to close in February 2008.
Barry Weiner, president of Enzo, said: “This proposed acquisition is one more step in our plan to build Enzo Life Sciences into a major participant in the research products global marketplace. Our intention is to continue to evaluate and consummate additional acquisitions that fit in with the infrastructure we have built for this division.”